This site is intended for healthcare professionals
  • Home
  • /
  • Journals
  • /
  • Lung Cancer
  • /
  • Osimertinib for the treatment of non-small cell lu...
Journal

Osimertinib for the treatment of non-small cell lung cancer.

Read time: 1 mins
Published:2nd Feb 2017
Author: Sun JM, Lee SH, Ahn JS, Park K, Ahn MJ.
Availability: Pay for access, or by subscription
Ref.:Expert Opin Pharmacother. 2017;18(2):225-231
DOI:10.1080/14656566.2017.1285283

Introduction: The T790 M mutation of the epidermal growth factor receptor (EGFR) gene is the most common mechanism underlying resistance to first- or second-generation EGFR tyrosine kinase inhibitors (TKIs) in patients with non-small cell lung cancer (NSCLC). Osimertinib, a third-generation EGFR TKI, shows robust clinical efficacy in patients with T790 M-mutated lung cancer.

Areas covered: We analyzed and reviewed clinical data for which patients who experienced acquired resistance to first- or second-generation EGFR TKIs. In addition, we briefly reviewed the potential role of osimertinib as a first-line therapy.

Expert opinion: Osimertinib was recently licensed for use in NSCLC patients with acquired resistance to other EGFR TKIs due to a T790 M mutation. However, unresolved issues surrounding the optimal application of osimertinib remain, specifically the development of a plasma-based mutation test to overcome the difficulty of repeat biopsy, the efficacy of osimertinib for brain or leptomeningeal metastases, the development of resistance to osimertinib, and the use of osimertinib therapy as a first-line treatment. Many ongoing studies are currently exploring these issues.

 

Read abstract on library site

Access full article